鈉離子通道阻滯劑藥物治療局灶性癲癇的中國專家應用共識_Journal of Epilepsy

Authors：

YANRaowei , ZHANGHesheng , HONGZhen , 吳欣桐　譯 ,  周東　審

Corresponding?author：

周東　審, Email: zhoudong666@yahoo.de.cn

Keywords：

癲癇; 局灶性; 鈉離子通道阻滯劑; 專家共識; 德爾菲

DOI：

10.7507/2096-0247.202508010

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

為鈉離子通道阻滯劑（sodium channel blockers，SCBs）在局灶性癲癇發作治療中的應用提供建議。由24名中國專家組成德爾菲共識組，通過3輪改良德爾菲法投票建立共識。指導委員會制定了9項關于SCBs治療局灶性癲癇發作的聲明，專家小組對這些聲明進行評估和投票。專家小組就奧卡西平、拉莫三嗪、拉考沙胺、艾司利卡西平、托吡酯、唑尼沙胺和西諾氨酯治療局灶性癲癇發作的建議以及SCBs的治療調整等9項聲明達成共識。通過改良德爾菲法形成了SCBs在局灶性癲癇發作中應用的中國專家共識,提出的推薦意見有助于指導臨床實踐和未來的研究。

Citation： YANRaowei, ZHANGHesheng, HONGZhen, 吳欣桐　譯, 周東　審. 鈉離子通道阻滯劑藥物治療局灶性癲癇的中國專家應用共識. Journal of Epilepsy, 2025, 11(5): 430-441. doi: 10.7507/2096-0247.202508010 Copy

1.	中國抗癲癇協會. 臨床診療指南. 癲癇病分冊. 人民衛生出版社, 2023.
2.	Fisher R S, Cross J H, French J A, et al. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia, 2017, 58(4): 522-530.
3.	Ioannou P, Foster D L, Sander J W, et al. The burden of epilepsy and unmet need in people with focal seizures. Brain Behav, 2022, 12(9): e2589.
4.	Yu P, Zhou D, Liao W, et al. An investigation of the characteristics of outpatients with epilepsy and antiepileptic drug utilization in a multicenter cross-sectional study in China. Epilepsy Behav, 2017, 69: 126-132.
5.	Kanner A M, Ashman E, Gloss D, et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology, 2018, 91(2): 74-81.
6.	中華醫學會神經病學分會, 中華醫學會神經病學分會腦電圖與癲癇學組. 中國成人局灶性癲癇規范化診治指南. 中華神經科雜志, 2022, 55(12): 1341-1352.
7.	L?scher W, Klein P. The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond. CNS Drugs, 2021, 35(9): 935-963.
8.	Nevitt S J, Sudell M, Cividini S, et al. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database Syst Rev, 2022, 4(4): Cd011412.
9.	Jeon J, Oh J, Yu KS. A meta-analysis: efficacy and safety of anti-epileptic drugs prescribed in Korea as monotherapy and adjunctive treatment for patients with focal epilepsy. Transl Clin Pharmacol, 2021, 29(1): 6-20.
10.	Margolis JM, Chu BC, Wang ZJ, et al. Effectiveness of antiepileptic drug combination therapy for partial-onset seizures based on mechanisms of action. JAMA Neurol, 2014, 71(8): 985-993.
11.	Nice. Epilepsies in children, young people and adults (NICE guideline NG217). 2022.
12.	Jones J, Hunter D. Consensus methods for medical and health services research. BMJ, 1995, 311(7001): 376-380.
13.	Wengert E R, Patel M K. The Role of the Persistent Sodium Current in Epilepsy. Epilepsy Curr, 2021, 21(1): 40-7.
14.	Goldfarb M. Voltage-gated sodium channel-associated proteins and alternative mechanisms of inactivation and block. Cell Mol Life Sci, 2012, 69(7): 1067-1076.
15.	Pal R, Kumar B, Akhtar MJ, et al. Voltage gated sodium channel inhibitors as anticonvulsant drugs: A systematic review on recent developments and structure activity relationship studies. Bioorg Chem, 2021, 115: 105230.
16.	Abdelsayed M, Sokolov S. Voltage-gated sodium channels: pharmaceutical targets via anticonvulsants to treat epileptic syndromes. Channels (Austin), 2013, 7(3): 146-152.
17.	Soares-Da-Silva P, Pires N, Bonifácio MJ, et al. Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action. Pharmacol Res Perspect, 2015, 3(2): e00124.
18.	Brodie M J. Sodium channel blockers in the treatment of epilepsy. CNS Drugs, 2017, 31(7): 527-534.
19.	Wang Y, Chen Z. An update for epilepsy research and antiepileptic drug development: Toward precise circuit therapy. Pharmacol Ther, 2019, 201: 77-93.
20.	Guignet M, Campbell A, White HS. Cenobamate (XCOPRI): can preclinical and clinical evidence provide insight into its mechanism of action? Epilepsia, 2020, 61(11): 2329-2339.
21.	Agbo J, Ibrahim ZG, Magaji SY, et al. Therapeutic efficacy of voltage-gated sodium channel inhibitors in epilepsy. Acta Epileptologica, 2023, 5(1): 16.
22.	Striano P, Minassian BA. From genetic testing to precision medicine in epilepsy. Neurotherapeutics, 2020, 17(2): 609-615.
23.	Brunklaus A, Brünger T, Feng T, et al. The gain of function SCN1A disorder spectrum: novel epilepsy phenotypes and therapeutic implications. Brain, 2022, 145(11): 3816-3831.
24.	Akhtar M J, Khan S A, Kumar B, et al. Role of sodium dependent SLC13 transporter inhibitors in various metabolic disorders. Mol Cell Biochem, 2023, 478(8): 1669-1687.
25.	Craig S. Phenytoin poisoning. Neurocrit Care, 2005, 3(2): 161-170.
26.	Johannessen S I, Ben-Menachem E. Management of focal-onset seizures: an update on drug treatment. Drugs, 2006, 66(13): 1701-1725.
27.	Barcs G, Walker E B, Elger C E, et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia, 2000, 41(12): 1597-1607.
28.	Bresnahan R, Atim-Oluk M, Marson A G. Oxcarbazepine add-on for drug-resistant focal epilepsy. Cochrane Database Syst Rev, 2020, 3(3): Cd012433.
29.	Beydoun A, Sachdeo R C, Kutluay E, et al. Sustained efficacy and long-term safety of oxcarbazepine: one-year open-label extension of a study in refractory partial epilepsy. Epilepsia, 2003, 44(9): 1160-1165.
30.	Kim J H, Lee S K, Loesch C, et al. Comparison of levetiracetam and oxcarbazepine monotherapy among Korean patients with newly diagnosed focal epilepsy: A long-term, randomized, open-label trial. Epilepsia, 2017, 58(4): e70-e74.
31.	Kang HC, Hu Q, Liu XY, et al. A follow-up study on newer anti-epileptic drugs as add-on and monotherapy for partial epilepsy in China. Chin Med J (Engl), 2012, 125(4): 646-651.
32.	Qin J, Wang Y, Huang XF, et al. Oxcarbazepine oral suspension in young pediatric patients with partial seizures and/or generalized tonic-clonic seizures in routine clinical practice in China: a prospective observational study. World J Pediatr, 2018, 14(3): 280-289.
33.	Chung S S, Johnson J K, Brittain S T, et al. Long-term efficacy and safety of adjunctive extended-release oxcarbazepine (Oxtellar XR(?) ) in adults with partial-onset seizures. Acta Neurol Scand, 2016, 133(2): 124-130.
34.	Chung S, Wang N, Hank N. Comparative retention rates and long-term tolerability of new antiepileptic drugs. Seizure, 2007, 16(4): 296-304.
35.	Matsuo F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U. S. Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology, 1993, 43(11): 2284-2291.
36.	Naritoku DK, Warnock CR, Messenheimer JA, et al. Lamotrigine extended-release as adjunctive therapy for partial seizures. Neurology, 2007, 69(16): 1610-1618.
37.	Ramaratnam S, Panebianco M, Marson AG. Lamotrigine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev, 2016, 2016(6): Cd001909.
38.	Kwan P, Brodie MJ, K?lvi?inen R, et al. Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallel-group trial. Lancet Neurol, 2011, 10(10): 881-890.
39.	Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet, 2007, 369(9566): 1000-1015.
40.	Marson A, Burnside G, Appleton R, et al. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet, 2021, 397(10282): 1363-1374.
41.	Ji L, Chen Y, Mao Z, et al. Efficacy and tolerability of lamotrigine in the treatment of focal epilepsy among children and adolescents: a meta-analysis. Transl Pediatr, 2021, 10(4): 807-818.
42.	Bootsma HP, Ricker L, Hekster YA, et al. The impact of side effects on long-term retention in three new antiepileptic drugs. Seizure, 2009, 18(5): 327-331.
43.	Chung S, Ben-Menachem E, Sperling MR, et al. Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical trials. CNS Drugs, 2010, 24(12): 1041-1054.
44.	Babar RK, Bresnahan R, Gillespie CS, et al. Lacosamide add-on therapy for focal epilepsy. Cochrane Database Syst Rev, 2021, 5(5): Cd008841.
45.	Baulac M, Rosenow F, Toledo M, et al. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol, 2017, 16(1): 43-54.
46.	Hong Z, Inoue Y, Liao W, et al. Efficacy and safety of adjunctive lacosamide for the treatment of partial-onset seizures in Chinese and Japanese adults: a randomized, double-blind, placebo-controlled study. Epilepsy Res, 2016, 127: 267-275.
47.	Farkas V, Steinborn B, Flamini J R, et al. Efficacy and tolerability of adjunctive lacosamide in pediatric patients with focal seizures. Neurology, 2019, 93(12): e1212-e1226.
48.	Ferreira JA, Le Pichon JB, Abdelmoity AT, et al. Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures - an open-label trial. Seizure, 2019, 71: 166-173.
49.	Hauff N S, Storstein A. Seizure Management and Prophylaxis Considerations in Patients with Brain Tumors. Curr Oncol Rep, 2023, 25(7): 787-792.
50.	Kwok CS, Johnson EL, Krauss GL. Comparing safety and efficacy of "third-generation" antiepileptic drugs: long-term extension and post-marketing treatment. CNS Drugs, 2017, 31(11): 959-974.
51.	Rosenfeld W, Fountain N B, Kaubrys G, et al. Safety and efficacy of adjunctive lacosamide among patients with partial-onset seizures in a long-term open-label extension trial of up to 8 years. Epilepsy Behav, 2014, 41: 164-170.
52.	Rosenow F, Kelemen A, Ben-Menachem E, et al. Long-term adjunctive lacosamide treatment in patients with partial-onset seizures. Acta Neurol Scand, 2016, 133(2): 136-144.
53.	Gil-Nagel A, Elger C, Ben-Menachem E, et al. Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies. Epilepsia, 2013, 54(1): 98-107.
54.	Chang X C, Yuan H, Wang Y, et al. Eslicarbazepine acetate add-on therapy for drug-resistant focal epilepsy. Cochrane Database Syst Rev, 2021, 6(6): Cd008907.
55.	Trinka E, Ben-Menachem E, Kowacs PA, et al. Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study. Epilepsia, 2018, 59(2): 479-491.
56.	Trinka E, Rocamora R, Chaves J, et al. Long-term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: an open-label extension study. Epilepsia, 2020, 61(10): 2129-2141.
57.	Kirkham F, Auvin S, Moreira J, et al. Efficacy and safety of eslicarbazepine acetate as adjunctive therapy for refractory focal-onset seizures in children: a double-blind, randomized, placebo-controlled, parallel-group, multicenter, phase-III clinical trial. Epilepsy Behav, 2020, 105: 106962.
58.	Fei Y, Shi R, Song Z. Adjunctive treatment with eslicarbazepine acetate for adults and children with focal-onset epilepsy: a meta-analysis. Front Neurol, 2022, 13: 909471.
59.	Hixson J, Gidal B, Pikalov A, et al. Efficacy and safety of eslicarbazepine acetate as a first or later adjunctive therapy in patients with focal seizures. Epilepsy Res, 2021, 171: 106561.
60.	Chung S, Sinha SR, Shah A, et al. Long-term safety and efficacy following conversion to eslicarbazepine acetate monotherapy in adults with focal seizures. Epilepsy Res, 2019, 153: 59-65.
61.	Chung SS, Fakhoury TA, Hogan RE, et al. Once-daily USL255 as adjunctive treatment of partial-onset seizures: randomized phase III study. Epilepsia, 2014, 55(7): 1077-1087.
62.	Pulman J, Jette N, Dykeman J, et al. Topiramate add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev, 2014(2): Cd001417.
63.	Gilliam FG, Veloso F, Bomhof MA, et al. A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy. Neurology, 2003, 60(2): 196-202.
64.	Nolan SJ, Sudell M, Tudur Smith C, et al. Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review. Cochrane Database Syst Rev, 2016, 12(12): Cd012065.
65.	Nevitt SJ, Sudell M, Tudur Smith C, et al. Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data revie. Cochrane Database Syst Rev, 2019, 6(6): Cd012065.
66.	Liu YT, Chen GT, Huang YC, et al. Effectiveness of dose-escalated topiramate monotherapy and add-on therapy in neurosurgery-related epilepsy: a prospective study. Medicine (Baltimore), 2020, 99(52): e23771.
67.	Chung SS, Hogan RE, Blatt I, et al. Long-term safety and sustained efficacy of USL255 (topiramate extended-release capsules) in patients with refractory partial-onset seizures. Epilepsy Behav, 2016, 59: 13-20.
68.	Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res, 1993, 15(1): 67-73.
69.	Lu Y, Xiao Z, Yu W, et al. Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy: a randomized, double-blind, placebo-controlled trial. Clin Drug Investig, 2011, 31(4): 221-229.
70.	Brigo F, Lattanzi S, Igwe SC, et al. Zonisamide add-on therapy for focal epilepsy. Cochrane Database Syst Rev, 2020, 7(7): Cd001416.
71.	Baulac M, Brodie MJ, Patten A, et al. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol, 2012, 11(7): 579-588.
72.	Eun SH, Kim HD, Eun BL, et al. Comparative trial of low- and high-dose zonisamide as monotherapy for childhood epilepsy. Seizure, 2011, 20(7): 558-563.
73.	Asadi-Pooya AA, Nei M, Sharan AD, et al. Antiepileptic drugs and relapse after epilepsy surgery. Epileptic Disord, 2008, 10(3): 193-198.
74.	Wroe SJ, Yeates AB, Marshall A. Long-term safety and efficacy of zonisamide in patients with refractory partial-onset epilepsy. Acta Neurol Scand, 2008, 118(2): 87-93.
75.	國家藥品監督管理局[Z]. 2024.
76.	Chung SS, French JA, Kowalski J, et al. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology, 2020, 94(22): e2311-e2322.
77.	Krauss GL, Klein P, Brandt C, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol, 2020, 19(1): 38-48.
78.	Steinhoff BJ, Ben-Menachem E, Brandt C, et al. Onset of efficacy and adverse events during Cenobamate titration period. Acta Neurol Scand, 2022, 146(3): 265-275.
79.	Sunita M, Louis F, Zhen H, et al. A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of adjunctive cenobamate in Asian patients with focal seizures, with optional open-label extension. AES Annual Meeting, Los Angeles, 2024.
80.	Lattanzi S, Trinka E, Zaccara G, et al. Third-generation antiseizure medications for adjunctive treatment of focal-onset seizures in adults: a systematic review and network meta-analysis. Drugs, 2022, 82(2): 199-218.
81.	Mulheron S, Leahy TP, Mcstravick M, et al. A comparison of cenobamate with other newer antiseizure medications for adjunctive treatment of focal-onset seizures: a systematic review and network meta-analysis. Seizure, 2024, 118: 80-90.
82.	Tong J, Ji T, Liu T, et al. Efficacy and safety of six new antiseizure medications for adjunctive treatment of focal epilepsy and epileptic syndrome: a systematic review and network meta-analysis. Epilepsy Behav, 2024, 152: 109653.
83.	Zhang H, Ou Z, Zhang E, et al. Efficacy and safety of add-on antiseizure medications for focal epilepsy: a network meta-analysis. Epilepsia Open, 2024, 22: 125-168.
84.	Vashi V, Rosenfeld W E, Ferrari L, et al. Pharmacokinetics of cenobamate as monotherapy compared with adjunctive therapy. Epilepsy Res, 2023, 195: 107185.
85.	Becker DA, Demko SA. Dose reduction and discontinuation of concomitant antiseizure medications after initiating cenobamate: a retrospective review. Epilepsy Res, 2023, 197: 107242.
86.	Becker M. Effectiveness of cenobamate as monotherapy: a retrospective claims-based analysis. American Epilepsy Society, 2023.
87.	Beltrán-Corbellini á, Romeral-Jiménez M, Mayo P, et al. Cenobamate in patients with highly refractory focal epilepsy: a retrospective real-world study. Seizure, 2023, 111: 71-7.
88.	Villanueva V, Santos-Carrasco D, Cabezudo-García P, et al. Real-world safety and effectiveness of cenobamate in patients with focal onset seizures: outcomes from an Expanded Access Program. Epilepsia Open, 2023, 8(3): 918-929.
89.	Pe?a-Ceballos J, Moloney P B, Munteanu T, et al. Adjunctive cenobamate in highly active and ultra-refractory focal epilepsy: a "real-world" retrospective study. Epilepsia, 2023, 64(5): 1225-1235.
90.	Varughese RT, Shah YD, Karkare S, et al. Adjunctive use of cenobamate for pediatric refractory focal-onset epilepsy: a single-center retrospective study. Epilepsy Behav, 2022, 130: 108679.
91.	Abou-Khalil B, Aboumatar S, Klein P, et al. Efficacy of cenobamate for uncontrolled focal seizures in patients with previous epilepsy-related surgery: post hoc analysis of a phase 3, multicenter, open-label study. Epilepsy Res, 2022, 184: 106952.
92.	Laskier V, Agyei-Kyeremateng KK, Eddy AE, et al. Cost-effectiveness of cenobamate for focal seizures in people with drug-resistant epilepsy. Epilepsia, 2023, 64(4): 843-856.
93.	Sperling MR, Klein P, Aboumatar S, et al. Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study. Epilepsia, 2020, 61(6): 1099-1108.
94.	French JA, Chung SS, Krauss GL, et al. Long-term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: Open-label extension of a randomized clinical study. Epilepsia, 2021, 62(9): 2142-2150.
95.	Sander JW, Rosenfeld WE, Halford JJ, et al. Long-term individual retention with cenobamate in adults with focal seizures: Pooled data from the clinical development program. Epilepsia, 2022, 63(1): 139-149.
96.	Campos MS, Ayres LR, Morelo MR, et al. Efficacy and tolerability of antiepileptic drugs in patients with focal epilepsy: systematic review and network meta-analyses. Pharmacotherapy, 2016, 36(12): 1255-1271.
97.	Brodie M J. Practical use of newer antiepileptic drugs as adjunctive therapy in focal epilepsy. CNS Drugs, 2015, 29(11): 893-904.
98.	Zaccara G, Lattanzi S, Brigo F. Cardiac adverse effects of antiseizure medications. Expert Opin Drug Saf, 2022, 21(5): 641-652.
99.	Feldman AE, Gidal BE. QTc prolongation by antiepileptic drugs and the risk of torsade de pointes in patients with epilepsy. Epilepsy Behav, 2013, 26(3): 421-426.
100.	Beydoun A, Dupont S, Zhou D, et al. Current role of carbamazepine and oxcarbazepine in the management of epilepsy. Seizure, 2020, 83: 251-63.
101.	Mintz M, Pina-Garza JE, Wolf SM, et al. Safety and Tolerability of adjunctive eslicarbazepine acetate in pediatric patients (aged 4-17 years) with focal seizures. J Child Neurol, 2020, 35(4): 265-273.
102.	Sankar R, Kirkham FJ, Holmes GL, et al. Long-term safety and tolerability of adjunctive eslicarbazepine acetate in children with focal seizures. Epilepsy Behav, 2020, 112: 107458.
103.	Costa R, Steinhoff B, Gama H, et al. Safety, Tolerability and efficacy of eslicarbazepine acetate as adjunctive therapy in patients aged ≥ 65 years with focal seizures. Drugs Aging, 2018, 35(12): 1109-1117.
104.	Brodie MJ. Tolerability and safety of commonly used antiepileptic drugs in adolescents and adults: a clinician's overview. CNS Drugs, 2017, 31(2): 135-147.
105.	Deng Y, Li S, Zhang L, et al. Association between HLA alleles and lamotrigine-induced cutaneous adverse drug reactions in Asian populations: a meta-analysis. Seizure, 2018, 60: 163-71.
106.	Chen CB, Hsiao YH, Wu T, et al. Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians. Neurology, 2017, 88(1): 78-86.
107.	Lee SK, Lee SA, Hong SB, et al. Long-term effects of adjunctive eslicarbazepine acetate in adult Asian patients with refractory focal seizures: Post hoc analysis of a phase III trial. Clin Transl Sci, 2024, 17(5): e13802.
108.	Yang E, Sunwoo J, Huh KY, et al. Pharmacokinetics and safety of cenobamate, a novel antiseizure medication, in healthy Japanese, and an ethnic comparison with healthy non-Japanese. Clin Transl Sci, 2022, 15(2): 490-500.
109.	Lu Y, Wang X, Li Q, et al. Tolerability and safety of topiramate in Chinese patients with epilepsy : an open-label, long-term, prospective study. Clin Drug Investig, 2007, 27(10): 683-690.
110.	Inoue Y, Liao W, Wang X, et al. Safety and efficacy of adjunctive lacosamide in Chinese and Japanese adults with epilepsy and focal seizures: a long-term, open-label extension of a randomized, controlled trial. Epilepsy Res, 2021, 176: 106705.
111.	Seiden LG, Connor GS. The importance of drug titration in the management of patients with epilepsy. Epilepsy Behav, 2022, 128: 108517.
112.	Gunasekera CL, Sirven JI, Feyissa AM. The evolution of antiseizure medication therapy selection in adults: Is artificial intelligence -assisted antiseizure medication selection ready for prime time? J Cent Nerv Syst Dis, 2023, 15: 11795735231209209.
113.	Perucca E, Perucca P, White H S, et al. Drug resistance in epilepsy. Lancet Neurol, 2023, 22(8): 723-734.
114.	Pazdera L, Sperling MR, Harvey JH, et al. Efficacy and safety of eslicarbazepine acetate monotherapy in patients converting from carbamazepine. Epilepsia, 2018, 59(3): 704-714.
115.	Brandt C, Sánchez-álvarez J C, Steinhoff B J, et al. Efficacy and safety of adjunctive cenobamate: Post-hoc analysis of study C017 in patients grouped by mechanism of action of concomitant antiseizure medications. Seizure, 2022, 96: 86-93.
116.	Sake J K, Hebert D, Isoj?rvi J, et al. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs, 2010, 24(12): 1055-1068.

1. 中國抗癲癇協會. 臨床診療指南. 癲癇病分冊. 人民衛生出版社, 2023.
2. Fisher R S, Cross J H, French J A, et al. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia, 2017, 58(4): 522-530.
3. Ioannou P, Foster D L, Sander J W, et al. The burden of epilepsy and unmet need in people with focal seizures. Brain Behav, 2022, 12(9): e2589.
4. Yu P, Zhou D, Liao W, et al. An investigation of the characteristics of outpatients with epilepsy and antiepileptic drug utilization in a multicenter cross-sectional study in China. Epilepsy Behav, 2017, 69: 126-132.
5. Kanner A M, Ashman E, Gloss D, et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology, 2018, 91(2): 74-81.
6. 中華醫學會神經病學分會, 中華醫學會神經病學分會腦電圖與癲癇學組. 中國成人局灶性癲癇規范化診治指南. 中華神經科雜志, 2022, 55(12): 1341-1352.
7. L?scher W, Klein P. The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond. CNS Drugs, 2021, 35(9): 935-963.
8. Nevitt S J, Sudell M, Cividini S, et al. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database Syst Rev, 2022, 4(4): Cd011412.
9. Jeon J, Oh J, Yu KS. A meta-analysis: efficacy and safety of anti-epileptic drugs prescribed in Korea as monotherapy and adjunctive treatment for patients with focal epilepsy. Transl Clin Pharmacol, 2021, 29(1): 6-20.
10. Margolis JM, Chu BC, Wang ZJ, et al. Effectiveness of antiepileptic drug combination therapy for partial-onset seizures based on mechanisms of action. JAMA Neurol, 2014, 71(8): 985-993.
11. Nice. Epilepsies in children, young people and adults (NICE guideline NG217). 2022.
12. Jones J, Hunter D. Consensus methods for medical and health services research. BMJ, 1995, 311(7001): 376-380.
13. Wengert E R, Patel M K. The Role of the Persistent Sodium Current in Epilepsy. Epilepsy Curr, 2021, 21(1): 40-7.
14. Goldfarb M. Voltage-gated sodium channel-associated proteins and alternative mechanisms of inactivation and block. Cell Mol Life Sci, 2012, 69(7): 1067-1076.
15. Pal R, Kumar B, Akhtar MJ, et al. Voltage gated sodium channel inhibitors as anticonvulsant drugs: A systematic review on recent developments and structure activity relationship studies. Bioorg Chem, 2021, 115: 105230.
16. Abdelsayed M, Sokolov S. Voltage-gated sodium channels: pharmaceutical targets via anticonvulsants to treat epileptic syndromes. Channels (Austin), 2013, 7(3): 146-152.
17. Soares-Da-Silva P, Pires N, Bonifácio MJ, et al. Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action. Pharmacol Res Perspect, 2015, 3(2): e00124.
18. Brodie M J. Sodium channel blockers in the treatment of epilepsy. CNS Drugs, 2017, 31(7): 527-534.
19. Wang Y, Chen Z. An update for epilepsy research and antiepileptic drug development: Toward precise circuit therapy. Pharmacol Ther, 2019, 201: 77-93.
20. Guignet M, Campbell A, White HS. Cenobamate (XCOPRI): can preclinical and clinical evidence provide insight into its mechanism of action? Epilepsia, 2020, 61(11): 2329-2339.
21. Agbo J, Ibrahim ZG, Magaji SY, et al. Therapeutic efficacy of voltage-gated sodium channel inhibitors in epilepsy. Acta Epileptologica, 2023, 5(1): 16.
22. Striano P, Minassian BA. From genetic testing to precision medicine in epilepsy. Neurotherapeutics, 2020, 17(2): 609-615.
23. Brunklaus A, Brünger T, Feng T, et al. The gain of function SCN1A disorder spectrum: novel epilepsy phenotypes and therapeutic implications. Brain, 2022, 145(11): 3816-3831.
24. Akhtar M J, Khan S A, Kumar B, et al. Role of sodium dependent SLC13 transporter inhibitors in various metabolic disorders. Mol Cell Biochem, 2023, 478(8): 1669-1687.
25. Craig S. Phenytoin poisoning. Neurocrit Care, 2005, 3(2): 161-170.
26. Johannessen S I, Ben-Menachem E. Management of focal-onset seizures: an update on drug treatment. Drugs, 2006, 66(13): 1701-1725.
27. Barcs G, Walker E B, Elger C E, et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia, 2000, 41(12): 1597-1607.
28. Bresnahan R, Atim-Oluk M, Marson A G. Oxcarbazepine add-on for drug-resistant focal epilepsy. Cochrane Database Syst Rev, 2020, 3(3): Cd012433.
29. Beydoun A, Sachdeo R C, Kutluay E, et al. Sustained efficacy and long-term safety of oxcarbazepine: one-year open-label extension of a study in refractory partial epilepsy. Epilepsia, 2003, 44(9): 1160-1165.
30. Kim J H, Lee S K, Loesch C, et al. Comparison of levetiracetam and oxcarbazepine monotherapy among Korean patients with newly diagnosed focal epilepsy: A long-term, randomized, open-label trial. Epilepsia, 2017, 58(4): e70-e74.
31. Kang HC, Hu Q, Liu XY, et al. A follow-up study on newer anti-epileptic drugs as add-on and monotherapy for partial epilepsy in China. Chin Med J (Engl), 2012, 125(4): 646-651.
32. Qin J, Wang Y, Huang XF, et al. Oxcarbazepine oral suspension in young pediatric patients with partial seizures and/or generalized tonic-clonic seizures in routine clinical practice in China: a prospective observational study. World J Pediatr, 2018, 14(3): 280-289.
33. Chung S S, Johnson J K, Brittain S T, et al. Long-term efficacy and safety of adjunctive extended-release oxcarbazepine (Oxtellar XR(?) ) in adults with partial-onset seizures. Acta Neurol Scand, 2016, 133(2): 124-130.
34. Chung S, Wang N, Hank N. Comparative retention rates and long-term tolerability of new antiepileptic drugs. Seizure, 2007, 16(4): 296-304.
35. Matsuo F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U. S. Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology, 1993, 43(11): 2284-2291.
36. Naritoku DK, Warnock CR, Messenheimer JA, et al. Lamotrigine extended-release as adjunctive therapy for partial seizures. Neurology, 2007, 69(16): 1610-1618.
37. Ramaratnam S, Panebianco M, Marson AG. Lamotrigine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev, 2016, 2016(6): Cd001909.
38. Kwan P, Brodie MJ, K?lvi?inen R, et al. Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallel-group trial. Lancet Neurol, 2011, 10(10): 881-890.
39. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet, 2007, 369(9566): 1000-1015.
40. Marson A, Burnside G, Appleton R, et al. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet, 2021, 397(10282): 1363-1374.
41. Ji L, Chen Y, Mao Z, et al. Efficacy and tolerability of lamotrigine in the treatment of focal epilepsy among children and adolescents: a meta-analysis. Transl Pediatr, 2021, 10(4): 807-818.
42. Bootsma HP, Ricker L, Hekster YA, et al. The impact of side effects on long-term retention in three new antiepileptic drugs. Seizure, 2009, 18(5): 327-331.
43. Chung S, Ben-Menachem E, Sperling MR, et al. Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical trials. CNS Drugs, 2010, 24(12): 1041-1054.
44. Babar RK, Bresnahan R, Gillespie CS, et al. Lacosamide add-on therapy for focal epilepsy. Cochrane Database Syst Rev, 2021, 5(5): Cd008841.
45. Baulac M, Rosenow F, Toledo M, et al. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol, 2017, 16(1): 43-54.
46. Hong Z, Inoue Y, Liao W, et al. Efficacy and safety of adjunctive lacosamide for the treatment of partial-onset seizures in Chinese and Japanese adults: a randomized, double-blind, placebo-controlled study. Epilepsy Res, 2016, 127: 267-275.
47. Farkas V, Steinborn B, Flamini J R, et al. Efficacy and tolerability of adjunctive lacosamide in pediatric patients with focal seizures. Neurology, 2019, 93(12): e1212-e1226.
48. Ferreira JA, Le Pichon JB, Abdelmoity AT, et al. Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures - an open-label trial. Seizure, 2019, 71: 166-173.
49. Hauff N S, Storstein A. Seizure Management and Prophylaxis Considerations in Patients with Brain Tumors. Curr Oncol Rep, 2023, 25(7): 787-792.
50. Kwok CS, Johnson EL, Krauss GL. Comparing safety and efficacy of "third-generation" antiepileptic drugs: long-term extension and post-marketing treatment. CNS Drugs, 2017, 31(11): 959-974.
51. Rosenfeld W, Fountain N B, Kaubrys G, et al. Safety and efficacy of adjunctive lacosamide among patients with partial-onset seizures in a long-term open-label extension trial of up to 8 years. Epilepsy Behav, 2014, 41: 164-170.
52. Rosenow F, Kelemen A, Ben-Menachem E, et al. Long-term adjunctive lacosamide treatment in patients with partial-onset seizures. Acta Neurol Scand, 2016, 133(2): 136-144.
53. Gil-Nagel A, Elger C, Ben-Menachem E, et al. Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies. Epilepsia, 2013, 54(1): 98-107.
54. Chang X C, Yuan H, Wang Y, et al. Eslicarbazepine acetate add-on therapy for drug-resistant focal epilepsy. Cochrane Database Syst Rev, 2021, 6(6): Cd008907.
55. Trinka E, Ben-Menachem E, Kowacs PA, et al. Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study. Epilepsia, 2018, 59(2): 479-491.
56. Trinka E, Rocamora R, Chaves J, et al. Long-term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: an open-label extension study. Epilepsia, 2020, 61(10): 2129-2141.
57. Kirkham F, Auvin S, Moreira J, et al. Efficacy and safety of eslicarbazepine acetate as adjunctive therapy for refractory focal-onset seizures in children: a double-blind, randomized, placebo-controlled, parallel-group, multicenter, phase-III clinical trial. Epilepsy Behav, 2020, 105: 106962.
58. Fei Y, Shi R, Song Z. Adjunctive treatment with eslicarbazepine acetate for adults and children with focal-onset epilepsy: a meta-analysis. Front Neurol, 2022, 13: 909471.
59. Hixson J, Gidal B, Pikalov A, et al. Efficacy and safety of eslicarbazepine acetate as a first or later adjunctive therapy in patients with focal seizures. Epilepsy Res, 2021, 171: 106561.
60. Chung S, Sinha SR, Shah A, et al. Long-term safety and efficacy following conversion to eslicarbazepine acetate monotherapy in adults with focal seizures. Epilepsy Res, 2019, 153: 59-65.
61. Chung SS, Fakhoury TA, Hogan RE, et al. Once-daily USL255 as adjunctive treatment of partial-onset seizures: randomized phase III study. Epilepsia, 2014, 55(7): 1077-1087.
62. Pulman J, Jette N, Dykeman J, et al. Topiramate add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev, 2014(2): Cd001417.
63. Gilliam FG, Veloso F, Bomhof MA, et al. A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy. Neurology, 2003, 60(2): 196-202.
64. Nolan SJ, Sudell M, Tudur Smith C, et al. Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review. Cochrane Database Syst Rev, 2016, 12(12): Cd012065.
65. Nevitt SJ, Sudell M, Tudur Smith C, et al. Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data revie. Cochrane Database Syst Rev, 2019, 6(6): Cd012065.
66. Liu YT, Chen GT, Huang YC, et al. Effectiveness of dose-escalated topiramate monotherapy and add-on therapy in neurosurgery-related epilepsy: a prospective study. Medicine (Baltimore), 2020, 99(52): e23771.
67. Chung SS, Hogan RE, Blatt I, et al. Long-term safety and sustained efficacy of USL255 (topiramate extended-release capsules) in patients with refractory partial-onset seizures. Epilepsy Behav, 2016, 59: 13-20.
68. Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res, 1993, 15(1): 67-73.
69. Lu Y, Xiao Z, Yu W, et al. Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy: a randomized, double-blind, placebo-controlled trial. Clin Drug Investig, 2011, 31(4): 221-229.
70. Brigo F, Lattanzi S, Igwe SC, et al. Zonisamide add-on therapy for focal epilepsy. Cochrane Database Syst Rev, 2020, 7(7): Cd001416.
71. Baulac M, Brodie MJ, Patten A, et al. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol, 2012, 11(7): 579-588.
72. Eun SH, Kim HD, Eun BL, et al. Comparative trial of low- and high-dose zonisamide as monotherapy for childhood epilepsy. Seizure, 2011, 20(7): 558-563.
73. Asadi-Pooya AA, Nei M, Sharan AD, et al. Antiepileptic drugs and relapse after epilepsy surgery. Epileptic Disord, 2008, 10(3): 193-198.
74. Wroe SJ, Yeates AB, Marshall A. Long-term safety and efficacy of zonisamide in patients with refractory partial-onset epilepsy. Acta Neurol Scand, 2008, 118(2): 87-93.
75. 國家藥品監督管理局[Z]. 2024.
76. Chung SS, French JA, Kowalski J, et al. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology, 2020, 94(22): e2311-e2322.
77. Krauss GL, Klein P, Brandt C, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol, 2020, 19(1): 38-48.
78. Steinhoff BJ, Ben-Menachem E, Brandt C, et al. Onset of efficacy and adverse events during Cenobamate titration period. Acta Neurol Scand, 2022, 146(3): 265-275.
79. Sunita M, Louis F, Zhen H, et al. A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of adjunctive cenobamate in Asian patients with focal seizures, with optional open-label extension. AES Annual Meeting, Los Angeles, 2024.
80. Lattanzi S, Trinka E, Zaccara G, et al. Third-generation antiseizure medications for adjunctive treatment of focal-onset seizures in adults: a systematic review and network meta-analysis. Drugs, 2022, 82(2): 199-218.
81. Mulheron S, Leahy TP, Mcstravick M, et al. A comparison of cenobamate with other newer antiseizure medications for adjunctive treatment of focal-onset seizures: a systematic review and network meta-analysis. Seizure, 2024, 118: 80-90.
82. Tong J, Ji T, Liu T, et al. Efficacy and safety of six new antiseizure medications for adjunctive treatment of focal epilepsy and epileptic syndrome: a systematic review and network meta-analysis. Epilepsy Behav, 2024, 152: 109653.
83. Zhang H, Ou Z, Zhang E, et al. Efficacy and safety of add-on antiseizure medications for focal epilepsy: a network meta-analysis. Epilepsia Open, 2024, 22: 125-168.
84. Vashi V, Rosenfeld W E, Ferrari L, et al. Pharmacokinetics of cenobamate as monotherapy compared with adjunctive therapy. Epilepsy Res, 2023, 195: 107185.
85. Becker DA, Demko SA. Dose reduction and discontinuation of concomitant antiseizure medications after initiating cenobamate: a retrospective review. Epilepsy Res, 2023, 197: 107242.
86. Becker M. Effectiveness of cenobamate as monotherapy: a retrospective claims-based analysis. American Epilepsy Society, 2023.
87. Beltrán-Corbellini á, Romeral-Jiménez M, Mayo P, et al. Cenobamate in patients with highly refractory focal epilepsy: a retrospective real-world study. Seizure, 2023, 111: 71-7.
88. Villanueva V, Santos-Carrasco D, Cabezudo-García P, et al. Real-world safety and effectiveness of cenobamate in patients with focal onset seizures: outcomes from an Expanded Access Program. Epilepsia Open, 2023, 8(3): 918-929.
89. Pe?a-Ceballos J, Moloney P B, Munteanu T, et al. Adjunctive cenobamate in highly active and ultra-refractory focal epilepsy: a "real-world" retrospective study. Epilepsia, 2023, 64(5): 1225-1235.
90. Varughese RT, Shah YD, Karkare S, et al. Adjunctive use of cenobamate for pediatric refractory focal-onset epilepsy: a single-center retrospective study. Epilepsy Behav, 2022, 130: 108679.
91. Abou-Khalil B, Aboumatar S, Klein P, et al. Efficacy of cenobamate for uncontrolled focal seizures in patients with previous epilepsy-related surgery: post hoc analysis of a phase 3, multicenter, open-label study. Epilepsy Res, 2022, 184: 106952.
92. Laskier V, Agyei-Kyeremateng KK, Eddy AE, et al. Cost-effectiveness of cenobamate for focal seizures in people with drug-resistant epilepsy. Epilepsia, 2023, 64(4): 843-856.
93. Sperling MR, Klein P, Aboumatar S, et al. Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study. Epilepsia, 2020, 61(6): 1099-1108.
94. French JA, Chung SS, Krauss GL, et al. Long-term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: Open-label extension of a randomized clinical study. Epilepsia, 2021, 62(9): 2142-2150.
95. Sander JW, Rosenfeld WE, Halford JJ, et al. Long-term individual retention with cenobamate in adults with focal seizures: Pooled data from the clinical development program. Epilepsia, 2022, 63(1): 139-149.
96. Campos MS, Ayres LR, Morelo MR, et al. Efficacy and tolerability of antiepileptic drugs in patients with focal epilepsy: systematic review and network meta-analyses. Pharmacotherapy, 2016, 36(12): 1255-1271.
97. Brodie M J. Practical use of newer antiepileptic drugs as adjunctive therapy in focal epilepsy. CNS Drugs, 2015, 29(11): 893-904.
98. Zaccara G, Lattanzi S, Brigo F. Cardiac adverse effects of antiseizure medications. Expert Opin Drug Saf, 2022, 21(5): 641-652.
99. Feldman AE, Gidal BE. QTc prolongation by antiepileptic drugs and the risk of torsade de pointes in patients with epilepsy. Epilepsy Behav, 2013, 26(3): 421-426.
100. Beydoun A, Dupont S, Zhou D, et al. Current role of carbamazepine and oxcarbazepine in the management of epilepsy. Seizure, 2020, 83: 251-63.
101. Mintz M, Pina-Garza JE, Wolf SM, et al. Safety and Tolerability of adjunctive eslicarbazepine acetate in pediatric patients (aged 4-17 years) with focal seizures. J Child Neurol, 2020, 35(4): 265-273.
102. Sankar R, Kirkham FJ, Holmes GL, et al. Long-term safety and tolerability of adjunctive eslicarbazepine acetate in children with focal seizures. Epilepsy Behav, 2020, 112: 107458.
103. Costa R, Steinhoff B, Gama H, et al. Safety, Tolerability and efficacy of eslicarbazepine acetate as adjunctive therapy in patients aged ≥ 65 years with focal seizures. Drugs Aging, 2018, 35(12): 1109-1117.
104. Brodie MJ. Tolerability and safety of commonly used antiepileptic drugs in adolescents and adults: a clinician's overview. CNS Drugs, 2017, 31(2): 135-147.
105. Deng Y, Li S, Zhang L, et al. Association between HLA alleles and lamotrigine-induced cutaneous adverse drug reactions in Asian populations: a meta-analysis. Seizure, 2018, 60: 163-71.
106. Chen CB, Hsiao YH, Wu T, et al. Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians. Neurology, 2017, 88(1): 78-86.
107. Lee SK, Lee SA, Hong SB, et al. Long-term effects of adjunctive eslicarbazepine acetate in adult Asian patients with refractory focal seizures: Post hoc analysis of a phase III trial. Clin Transl Sci, 2024, 17(5): e13802.
108. Yang E, Sunwoo J, Huh KY, et al. Pharmacokinetics and safety of cenobamate, a novel antiseizure medication, in healthy Japanese, and an ethnic comparison with healthy non-Japanese. Clin Transl Sci, 2022, 15(2): 490-500.
109. Lu Y, Wang X, Li Q, et al. Tolerability and safety of topiramate in Chinese patients with epilepsy : an open-label, long-term, prospective study. Clin Drug Investig, 2007, 27(10): 683-690.
110. Inoue Y, Liao W, Wang X, et al. Safety and efficacy of adjunctive lacosamide in Chinese and Japanese adults with epilepsy and focal seizures: a long-term, open-label extension of a randomized, controlled trial. Epilepsy Res, 2021, 176: 106705.
111. Seiden LG, Connor GS. The importance of drug titration in the management of patients with epilepsy. Epilepsy Behav, 2022, 128: 108517.
112. Gunasekera CL, Sirven JI, Feyissa AM. The evolution of antiseizure medication therapy selection in adults: Is artificial intelligence -assisted antiseizure medication selection ready for prime time? J Cent Nerv Syst Dis, 2023, 15: 11795735231209209.
113. Perucca E, Perucca P, White H S, et al. Drug resistance in epilepsy. Lancet Neurol, 2023, 22(8): 723-734.
114. Pazdera L, Sperling MR, Harvey JH, et al. Efficacy and safety of eslicarbazepine acetate monotherapy in patients converting from carbamazepine. Epilepsia, 2018, 59(3): 704-714.
115. Brandt C, Sánchez-álvarez J C, Steinhoff B J, et al. Efficacy and safety of adjunctive cenobamate: Post-hoc analysis of study C017 in patients grouped by mechanism of action of concomitant antiseizure medications. Seizure, 2022, 96: 86-93.
116. Sake J K, Hebert D, Isoj?rvi J, et al. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs, 2010, 24(12): 1055-1068.

Previous Article
Real experience of fertility in decision-making:a qualitative study of reproductive-age women with epilepsy
Next Article
PCDH19 基因變異致叢集性癲癇三例臨床特征及文獻復習

Journal of Epilepsy

鈉離子通道阻滯劑藥物治療局灶性癲癇的中國專家應用共識

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content